Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The use of computer drop-down menus organized by generic name was identified as a source of medication errors in the clinical program, mixing up Kadcyla with unconjugated trastuzumab. The solution of adding a three-letter prefix to Kadcyla’s nonproprietary name also seems to be the fix for biosimilars.
You may also be interested in...
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.